Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLENDER Trial
NCT03841084Phase 2Completed
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
- Start
- Sep 2019
- Primary completion
- Jun 2023
- Modality
- Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxygen in heart failure (HF) and cardiac arrest (SCA) (2 arms), sponsored by Australian and New Zealand Intensive Care Research Centre. Primary endpoint: Number of alive and ICU-free days at 28 days. Started Sep 2019; status: completed.
02
Drugs
oxygen
03
Conditions
heart failure (HF)cardiac arrest (SCA)
Beyond the preview
Go deeper on NCT03841084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03841084.